Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Accenture
Moodys
Dow
Fish and Richardson
Harvard Business School
Cerilliant
Daiichi Sankyo
QuintilesIMS

Generated: June 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,012,469

« Back to Dashboard

Which drugs does patent 9,012,469 protect, and when does it expire?

Patent 9,012,469 protects MOVANTIK and is included in one NDA.

This patent has thirty-six patent family members in thirty-three countries.
Summary for Patent: 9,012,469
Title:Crystalline naloxol-peg conjugate
Abstract: Naloxol-polyethlyene glycol conjugates of the formula: are provided in oxalate or phosphate salt forms including crystalline forms. Methods of preparing the salt forms and pharmaceutical compositions comprising the salt forms are also provided.
Inventor(s): .ANG.slund; Bengt Leonard (Alderley Park, GB), Aurell; Carl-Johan (Alderley Park, GB), Bohlin; Martin Hans (Alderley Park, GB), Healy; Eric Thomas (Waltham, MA), Jensen; David Richard (Waltham, MA), Jonaitis; David Thomas (Waltham, MA), Parent; Stephan (Waltham, MA), Sebhatu; Tesfai (Alderley Park, GB), Ymen; Bo Ingvar (Alderley Park, GB)
Assignee: AstraZeneca AB (Sodertalje, SE) Nektar Therapeutics (San Francisco, CA)
Application Number:13/823,953
Patent Claim Types:
see list of patent claims
Compound; Use; Formulation; Composition; Dosage form;

Drugs Protected by US Patent 9,012,469

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Astrazeneca Pharms MOVANTIK naloxegol oxalate TABLET;ORAL 204760-001 Sep 16, 2014 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Astrazeneca Pharms MOVANTIK naloxegol oxalate TABLET;ORAL 204760-002 Sep 16, 2014 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 9,012,469

PCT Information
PCT FiledSeptember 29, 2011PCT Application Number:PCT/SE2011/051161
PCT Publication Date:April 05, 2012PCT Publication Number: WO2012/044243

Non-Orange Book US Patents Family Members for Patent 9,012,469

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,149,539 Crystalline naloxol-PEG conjugate ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 9,012,469

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 083268 ➤ Try a Free Trial
Australia 2011307608 ➤ Try a Free Trial
Canada 2812649 ➤ Try a Free Trial
Chile 2013000866 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Fish and Richardson
Federal Trade Commission
Julphar
Farmers Insurance
McKesson
Cipla
US Department of Justice
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.